Aston University (AU) has more than 30 years of expertise in laser development and biotissue-light interaction research, and has coordinated numerous biophotonics projects. Indeed, the foundational science that GlioLighT is built upon was generated by AU, making them uniquely suited to lead GlioLighT and manufacture and develop DLT technology.
The University of Barcelona (UB) has over 30 years of experience studying brain structure and function in physiological and pathological brain conditions in vitro and in vivo. Having spent the last 5 years modulating brain circuits with light, UB are ideally positioned to research the potential side-effects of DLT on the brain. With this expertise and infrastructure, UB will lead research on the potential side-effects and safety of DLT on the brain whilst supporting UM to interpret their results on the mechanisms of action of DLT on glioma.
Ludwig-Maximilians University Munich (LMU) has more than 30 years of experience and expertise in a range of areas, from laboratory research on the underlying physical and biological mechanisms to clinical application and approval studies for patient care. The group is a cooperation partner of various companies and medical departments, including neurosurgery. LMU will support the partners with regard to light dosimetry and light/PDT-induced effects on biological cells and tissue in vitro and in vivo.
The University of Mainz (UM) has more than 20 years of expertise in glioma research, particularly in cell biology and neuro-immuno-oncology. UM also brings to GlioLighT their own 3D co-culture model, which represents a very valuable approach to study biological processes in an environment that mimics that of the genuine brain/tumour, but which is much more versatile and ethically responsible than animal testing.
Modulight Corporation is a certified semiconductor company providing value-added solutions to optical applications for medical, life sciences, custom and industrial applications. Modulight provide biomedical lasers for oncology, genetics and ophthalmology, supporting laser solutions like system integration service and laser design & manufacturing, with existing platforms currently being used commercially and in multiple clinical trials in the US and Europe in oncology and ophthalmology area.
Modus managers bring a wide breadth of scientific knowledge from experience on previous projects, have backgrounds in a variety of science disciplines, are WIPO trained for IP management, and provide an established methodology for innovation management (SQUADRONTM). As such, MOD will support AU in coordinating GlioLighT, ensure the project progresses smoothly, and lead communication, dissemination, and exploitation activities.
